ECSP105695A - Proceso para la fabricacion de valsartan - Google Patents

Proceso para la fabricacion de valsartan

Info

Publication number
ECSP105695A
ECSP105695A EC2010005695A ECSP105695A ECSP105695A EC SP105695 A ECSP105695 A EC SP105695A EC 2010005695 A EC2010005695 A EC 2010005695A EC SP105695 A ECSP105695 A EC SP105695A EC SP105695 A ECSP105695 A EC SP105695A
Authority
EC
Ecuador
Prior art keywords
valsartan
manufacturing process
angiotensin
receptor antagonist
receptor
Prior art date
Application number
EC2010005695A
Other languages
English (en)
Inventor
Gottfried Sedelmeier
Hans Hirt
Christoph Krell
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9944606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP105695(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP105695A publication Critical patent/ECSP105695A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente invención se refiere a un proceso para la fabricación de Valsartan, un bloqueador del receptor de angiotensina (ARB; también denominado antagonista del receptor de angiotensina II ó antagonista del receptor AT1), y sales del mismo, a intermediarios novedosos, y a los pasos del proceso.
EC2010005695A 2002-09-23 2010-02-11 Proceso para la fabricacion de valsartan ECSP105695A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0222056.4A GB0222056D0 (en) 2002-09-23 2002-09-23 Process for the manufacture of organic compounds

Publications (1)

Publication Number Publication Date
ECSP105695A true ECSP105695A (es) 2010-03-31

Family

ID=9944606

Family Applications (2)

Application Number Title Priority Date Filing Date
EC2005005695A ECSP055695A (es) 2002-09-23 2005-03-21 Proceso para la fabricacion de valsartan
EC2010005695A ECSP105695A (es) 2002-09-23 2010-02-11 Proceso para la fabricacion de valsartan

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EC2005005695A ECSP055695A (es) 2002-09-23 2005-03-21 Proceso para la fabricacion de valsartan

Country Status (30)

Country Link
US (3) US20060069268A1 (es)
EP (2) EP1546122B8 (es)
JP (2) JP4787498B2 (es)
KR (2) KR20110015703A (es)
CN (2) CN101153027B (es)
AR (1) AR041360A1 (es)
AU (1) AU2003270241B2 (es)
BR (1) BR0314132A (es)
CA (1) CA2502629A1 (es)
CY (1) CY1107878T1 (es)
DE (1) DE60317690T2 (es)
DK (1) DK1546122T3 (es)
EC (2) ECSP055695A (es)
ES (1) ES2295623T3 (es)
GB (1) GB0222056D0 (es)
HK (1) HK1079771A1 (es)
IL (1) IL167426A (es)
MX (1) MXPA05003140A (es)
MY (1) MY138618A (es)
NO (2) NO20051970L (es)
NZ (2) NZ538927A (es)
PE (2) PE20050088A1 (es)
PL (1) PL374862A1 (es)
PT (1) PT1546122E (es)
RU (2) RU2348619C2 (es)
SG (1) SG155049A1 (es)
SI (1) SI1546122T1 (es)
TW (2) TWI329106B (es)
WO (1) WO2004026847A1 (es)
ZA (1) ZA200502159B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199144B2 (en) 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
ATE393764T1 (de) 2003-03-17 2008-05-15 Teva Pharma Polymorphe formen von valsartan
US7378531B2 (en) 2003-04-21 2008-05-27 Teva Pharmaceutical Industries Ltd Process for the preparation of valsartan
WO2004094391A2 (en) * 2003-04-21 2004-11-04 Teva Pharmaceutical Industries Ltd. Process for the preparation of valsartan and intermediates thereof
GB0316546D0 (en) * 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
GB0402262D0 (en) * 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
EP1661891A1 (en) * 2004-11-30 2006-05-31 KRKA, D.D., Novo Mesto A process for the synthesis of valsartan
GB0514206D0 (en) 2005-07-11 2005-08-17 Novartis Ag Organic compounds
ES2288376B1 (es) * 2005-10-20 2008-11-01 Inke, S.A. Procedimiento para la obtencion de intermedios utiles en la obtencion de un compuesto farmaceuticamente activo.
WO2007057919A2 (en) * 2005-10-25 2007-05-24 Alembic Limited An improved process for preparation of (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)biphenyl-4-ylmethyl]-amine
US7880015B2 (en) * 2006-07-03 2011-02-01 Aurobindo Pharma Ltd. Process for the preparation of angiotensin II antagonist
ES2315141B1 (es) * 2006-11-23 2009-12-22 Quimica Sintetica, S.A Procedimiento para la preparacion de cardesartan cilexetilo en forma cristalina.
CN101200455B (zh) * 2007-09-29 2010-08-18 泰兴市江神化工有限公司 沙坦类治疗高血压药物主环5-(4'-甲酰基联苯-2-基)-1h-四氮唑的制备方法
US7943794B2 (en) * 2008-02-13 2011-05-17 Ranbaxy Laboratories Limited Processes for the preparation of intermediates of valsartan
KR101012135B1 (ko) * 2008-12-18 2011-02-07 주식회사 대희화학 발사르탄 메틸 에스테르의 제조방법
EP2316821A1 (en) 2009-10-27 2011-05-04 Novartis AG Process for the manufacture of organic compounds
JP2013532707A (ja) * 2010-08-03 2013-08-19 ノバルティス アーゲー 高結晶性バルサルタン
CN102351804B (zh) * 2011-09-30 2013-07-31 浙江新赛科药业有限公司 一种缬沙坦消旋体的回收方法
CN103554047A (zh) * 2013-10-11 2014-02-05 镇江市高等专科学校 制备缬沙坦的方法
CN103923028B (zh) * 2014-05-04 2017-05-24 青岛雪洁助剂有限公司 一种缬沙坦甲酯的制备方法
CN104072433A (zh) * 2014-07-16 2014-10-01 南京正大天晴制药有限公司 一种缬沙坦的水解杂质化合物及其制备方法、检测方法和用途
CN104151199A (zh) * 2014-08-13 2014-11-19 苏州卫生职业技术学院 一种缬沙坦的合成方法
CN104844476B (zh) * 2015-04-03 2016-08-24 李凌 一种医药中间体联苯类化合物的合成方法
CN112014479A (zh) * 2019-05-28 2020-12-01 珠海润都制药股份有限公司 一种缬沙坦中正戊酰氯的检测方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19675036I2 (de) * 1990-02-19 2004-10-21 Novartis Ag Acylverbindungen.
US5260325A (en) * 1991-08-19 1993-11-09 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking tertiary amides
EP0550313A1 (fr) * 1991-12-30 1993-07-07 Synthelabo Nouveaux dérivés de 2-(tétrazol-5-yl)-(1,1'-biphényle), leur préparation et leur utilisation comme intermédiaires de synthèse
FR2688503B1 (fr) * 1992-03-16 1994-05-06 Synthelabo Procede de preparation de derives de 2-(tetrazol-5-yl)-[1,1'-biphenyle].
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
JPH08165292A (ja) * 1993-10-07 1996-06-25 Techno Res Kk アデニン誘導体、その製造法及び用途
US5468867A (en) * 1994-05-27 1995-11-21 Syntex (U.S.A.) Inc. Process for preparing1-butyl-2-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl1-1H-indole-3-carboxylic acid
US5412102A (en) * 1994-05-27 1995-05-02 Syntex (U.S.A.) Inc. Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid
DK0782996T3 (da) * 1994-09-20 1999-09-20 Wakunaga Seiyaku Kk Fremgangsmåde til fremstilling af N-biphenylmethylthiadiazolinderivat eller salt deraf og mellemprodukt til fremstilling af
EA000622B1 (ru) * 1995-06-07 1999-12-29 Американ Хоум Продактс Корпорейшн Способ получения производных дифенила
CN1137887C (zh) * 2000-04-07 2004-02-11 常州四药制药有限公司 一种合成缬沙坦的改进方法
DE60135560D1 (de) * 2000-07-19 2008-10-09 Novartis Ag Valsartan salze
GB0402262D0 (en) * 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds

Also Published As

Publication number Publication date
JP2010254709A (ja) 2010-11-11
IL167426A (en) 2010-11-30
PL374862A1 (en) 2005-11-14
RU2005112444A (ru) 2006-01-20
ECSP055695A (es) 2005-05-30
RU2008133680A (ru) 2010-02-27
KR20110015703A (ko) 2011-02-16
SI1546122T1 (sl) 2008-04-30
CY1107878T1 (el) 2013-06-19
PE20091387A1 (es) 2009-10-13
US20060069268A1 (en) 2006-03-30
NO20051970L (no) 2005-06-16
EP1546122B1 (en) 2007-11-21
BR0314132A (pt) 2005-06-28
TWI338003B (en) 2011-03-01
MY138618A (en) 2009-07-31
PE20050088A1 (es) 2005-02-21
CN101153027A (zh) 2008-04-02
NZ538927A (en) 2008-05-30
JP2006502178A (ja) 2006-01-19
HK1079771A1 (en) 2006-04-13
ZA200502159B (en) 2005-09-21
EP1546122A1 (en) 2005-06-29
PT1546122E (pt) 2008-02-14
KR20050057529A (ko) 2005-06-16
EP1546122B8 (en) 2008-05-28
CN1688556A (zh) 2005-10-26
WO2004026847A1 (en) 2004-04-01
RU2412173C2 (ru) 2011-02-20
CN101153027B (zh) 2010-08-18
ES2295623T3 (es) 2008-04-16
JP4787498B2 (ja) 2011-10-05
NO20110856L (no) 2005-06-16
US20090111995A1 (en) 2009-04-30
CA2502629A1 (en) 2004-04-01
AU2003270241A1 (en) 2004-04-08
DK1546122T3 (da) 2008-03-03
US20100249429A1 (en) 2010-09-30
MXPA05003140A (es) 2005-06-22
TW201016673A (en) 2010-05-01
RU2348619C2 (ru) 2009-03-10
TW200413337A (en) 2004-08-01
CN100357279C (zh) 2007-12-26
SG155049A1 (en) 2009-09-30
EP1878729A1 (en) 2008-01-16
TWI329106B (en) 2010-08-21
DE60317690D1 (de) 2008-01-03
NZ566863A (en) 2009-08-28
AR041360A1 (es) 2005-05-11
GB0222056D0 (en) 2002-10-30
AU2003270241B2 (en) 2007-08-23
DE60317690T2 (de) 2008-10-30

Similar Documents

Publication Publication Date Title
ECSP105695A (es) Proceso para la fabricacion de valsartan
CR7680A (es) Un nuevo proceso para la sintesis de agomelatina
CL2009001063A1 (es) Uso de una combinacion de un compuesto derivado de n-quinoliniloxifenil-n-fenilciclopropanodicarboxamida y un inhibidor de erbb seleccionado entre lapatinib, erlotinib, gefitinib, trastuzumab, cetuximab, para eltratamiento de canceres.
NI200500031A (es) Nuevos procesos para la sintesis de ivabradine y ademas sales que la contienen con un acido aceptable farmaceuticamente.
CY1112467T1 (el) Παραγωγα 1-θειο-d-γλυκιτολης
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
BRPI0615705A2 (pt) processo para preparar um composto, e, composto
NO20080761L (no) Acykliske Ikur inhibitorer
BR0317139A (pt) Métodos e compostos para produção de inibidores de dipeptidil peptidase iv e seus intermediários
MX2010002836A (es) Bortezomib y proceso para la produccion del mismo.
MX2009004900A (es) Arilamidas sustituidas por tiazol u oxazol.
CY1110520T1 (el) Παραγωγα 5-υποκατεστημενης κινολινης και ισοκινολινης· μεθοδος για την παραγωγη τους και η χρηση τους ως αντιφλεγμονωδη
NO20071254L (no) Fremgangsmate for fremstilling av irbesartan og mellomprodukter derav.
TW200628174A (en) Bilayer tablet
NO20075706L (no) Pyrrolopyridinbaserte inhibitorer av dipeptidylpeptidase IV og metoder
TW200640912A (en) Novel processes for the preparation of a 2H-chromene
MEP15908A (en) 1-amino-2-oxy-substituted tetrahydronaphtalene derivatives, methods for the production thereof, and their use as antiphlogistics
TW200619206A (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
EA200870038A1 (ru) Способ получения аминов
NO20053208D0 (no) Metode for reduktiv dehalogenering.
CO6531487A2 (es) Proceso para la elaboración de compuestos orgánicos
ITMI20060488A1 (it) Procedimento per la preparazione di 3,4-bis trifluoronetil-n-metilbenzilammina
CY1105785T1 (el) Μεθοδοι παρασκευης της 2-(7-χλωρο-1,8-ναφθυριδιν-2-υλ)-3-(5-μεθυλ-2-οξο-εξυλ)-1-ισοϊνδολινονης
NO20074880L (no) Proteaseinhibitor forloper syntese
WO2007017469A3 (en) Process for preparing an angiotensin ii receptor antagonist